1. Background
2. Objectives
3. Methods
3.1. Reagents
3.2. Animals
3.3. Induction of Colitis
3.4. Experimental Groups
3.5. Isolation and Expansion of MSCs
3.6. Charecterization of MSCs
3.7. Evaluation of Animal’s Well-Being
| Score | Weight Loss, % | Blood Feces | Stool Consistency |
|---|---|---|---|
| 0 | Negative | Negative | Normal |
| 1 | 1 - 9 | Red | Soft |
| 2 | 10 - 19 | Dark red | Very soft |
| 3 | < 20% | Black | Diarrhea |
aThe disease activity index was calculated as the sum of scores of all criteria.
3.8. Colonic Homogenate
3.9. Assessment of Biochemical Changes in the Colonic Homogenate
3.10. Statistical Analysis
4. Results
Characterization of mesenchymal stem cells. A, subculture 3 of cells depicted large, flattened or fibroblast-like morphology; the typical shape of MSCs (X40); B, the immunophenotypic characterization of MSCs by flow cytometry; C, the results of co-culture of MSCs T-lymphocytes. *P < 0.01 vs. T-lymphocytes without MSCs.
aThe values are expressed as mean ± SD.
bP < 0.001 vs. normal rats.
cP < 0.01 vs. the colitis group.
Evaluation of biochemical changes in the colonic tissue. The levels of myeloperoxidase activity (A) and nitric oxide (B) were downregulated in the gut of E2-MSCs-treated rats more than the untreated-MSCs group. Moreover, treatment with E2-MSCs and MSCs could decrease the level of MDA in acetic acid-induced colitis. Nevertheless, there were no significant differences in MDA activity between E2-MSCs groupand healthy rats (C). Also, both therapy could equally enhance the level of total protein in the colonic homogenate compared to control positive rats (D). *P < 0.001 vs. control positive rats; #P < 0.01 vs. MSCs-treated group.
Assessment of cytokines profile in the colonic tissue. The levels of TNF-α, IL-1β, and IL-6 were reduced in both treatment groups in a significant manner compared to the control rats with colitis. Cell therapy with E2-primed MSCs caused a significant reduction in IL-6 and IL-1β production compared to the MSCs group. In addition, there were no significant differences in IL-6 levels between the E2-MSCs groups and healthy rats. **P < 0.001 and *P < 0.01 vs. the control positive rats; #P < 0.01 vs. the MSCs-treated group.



